RedChip Issues Research Profile on Exeo Entertainment

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
RedChip Issues Research Profile on Exeo Entertainment

ORLANDO, Fla., July 24, 2014 (GLOBE NEWSWIRE) -- RedChip Companies, Inc., today announced it has issued a research profile on Exeo Entertainment, Inc. (OTCQB:EXEO), a company that develops, acquires, manufactures, licenses and distributes unique products in the video gaming, music, and smart TV sectors.

To receive a complimentary copy of the RedChip Research Report for EXEO, please visit: http://www.redchip.com/company/home/EXEO

About RedChip Companies, Inc.

RedChip Companies, an Inc. 5000 company, is an international small-cap research, investor relations, and media company headquartered in Orlando, Florida; with affiliate offices in San Francisco, Pittsburgh, and Seoul. RedChip delivers concrete, measurable results for its clients through its extensive global network of small-cap institutional and retail investors. RedChip has developed the most comprehensive platform of products and services for small-cap companies, including: RedChip Research™, Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences, Virtual Conferences, "The RedChip Money Report: Small Stocks Big Money"™ television show, Shareholder Intelligence, Strategic Marketing, Crisis Management, Social Media and Blogging Services, and Webcasts. To learn more about RedChip's products and services, please visit:

http://www.redchip.com/our_services

"Discovering Tomorrow's Blue Chips Today"™

Disclosure

The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information). Investors are expected to take full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. Investors are further cautioned that small-cap and microcap stocks have additional risks that may result in trading at a discount to their peers. Liquidity risk, caused by small trading floats and very low trading volume can lead to large spreads and high volatility in stock price. Small-cap and microcap stocks may also have significant company-specific risks that contribute to lower valuations. Investors need to be aware of the higher probability of financial default and higher degree of financial distress inherent in the small-cap and microcap segments of the market. The information, opinions, data, quantitative and qualitative statements contained herein have been obtained from sources believed to be reliable but have not been independently verified and are not guaranteed as to accuracy, nor does it purport to be a complete analysis of every material fact regarding the company, industry, or security. The information, opinions, or recommendations are solely for advisory and informational purposes and are only valid as of the date appearing on the report and are subject to change without notice. Statements that are not historical facts are "forward-looking statements" that involve risks and uncertainties. "Forward-looking statements" as defined under Section 27A of the Securities Act of 1933, Section 21B of the Securities Exchange Act of 1934 and the Private Securities Litigation Act of 1995 include words such as "opportunities," "trends," "potential," "estimates," "may," "will," "could," "should," "anticipates," "expects" or comparable terminology or by discussions of strategy. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of the company's or our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. Investors should consider these factors in evaluating the forward-looking statements contained herein and not place undue reliance upon such statements. Investors are encouraged to read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org . Exeo Entertainment, Inc. is a client of RedChip Companies, Inc. Exeo Entertainment, Inc. agreed to pay RedChip Companies, Inc. a monthly cash fee, plus 400,000 shares of Rule 144 stock for twelve (12) months of RedChip investor awareness services. Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.

RedChip Companies Inc. 1-800-REDCHIP (733-2447) http://www.redchip.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 255

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 266

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 176

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 210

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 113

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 115

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 59

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Scent Dispensing Solution for Hunting Enthusiasts

Updated Category News Views 168

Introducing a Game-Changing Scent Dispensing System In the world of hunting, attracting game animals can often be a challenge. A new invention, designed specifically for this purpose, promises to make the process much simpler and more efficient. The inventor of this innovative scent dispensing system, THE DRAG LINE PRO, envisioned a better way to utilize a scent drag...

Continue Reading
Corby Spirit and Wine Limited Reports Impressive Fiscal Results

Updated Category News Views 295

Corby Spirit and Wine Limited Announces Strong Fiscal Performance Corby Spirit and Wine Limited, renowned for its position as a leading Canadian manufacturer, marketer, and importer of spirits, has recently unveiled impressive results for its fourth quarter and full-year fiscal 2025. The company demonstrated significant growth in revenue, achieving total revenues of...

Continue Reading
Sezzle Faces Setback as Short-Seller Targets Its Practices

Updated Category News Views 113

Sezzle's Stock Takes a Dramatic Hit Recently, the buy now, pay later (BNPL) provider Sezzle experienced a significant decrease in its stock value. Reports indicate that shares fell over 28.6% in early trading after Hindenburg Research disclosed a short position against the company due to concerns surrounding risky lending practices. Understanding the Short-Selling...

Continue Reading
Exploring the Growth of $1000 in Marsh & McLennan Cos Today

Updated Category News Views 116

Understanding Long-Term Investment in Marsh & McLennan Marsh & McLennan Cos (NYSE: MMC) has established itself as a financial powerhouse, outperforming the market consistently over the past two decades. Investors have experienced an impressive annualized return of 13.31%, showcasing the benefits of long-term investment strategies. The Value of Persistence in Investing...

Continue Reading
Discover Toll Brothers' Latest Luxury Homes at Overbrook Estates

Updated Category News Views 671

Introducing Overbrook Estates by Toll Brothers Toll Brothers, Inc. (NYSE:TOL), a renowned name in luxury homebuilding, excitedly unveils its newest community: Overbrook Estates. This anticipated project is set to grace the Huntersville area, offering homebuyers elegant living in a master-planned environment. Positioned conveniently off Highway 77, this prime location sets...

Continue Reading